Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Merus N.V. - Common Shares
(NQ:
MRUS
)
90.00
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merus N.V. - Common Shares
< Previous
1
2
3
4
5
6
7
8
Next >
Discover the top movers in Friday's pre-market session.
↗
May 23, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
May 22, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus Announces the Journal Publication of Petosemtamab Mechanism of Action
May 15, 2025
From
Merus N.V.
Via
GlobeNewswire
What's Going On With Merus Stock Monday?
↗
January 13, 2025
Merus announced a research collaboration and license agreement with Biohaven.
Via
Benzinga
Merus to Present at BofA Securities 2025 Health Care Conference
May 08, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
May 07, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
April 23, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
April 01, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
February 27, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus to Present at Upcoming Investor Conferences
February 25, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus Shares Are Up Today: What's Going On?
↗
February 18, 2025
Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for...
Via
Benzinga
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
February 18, 2025
This marks the second BTD for petosemtamab in HNSCC
From
Merus N.V.
Via
GlobeNewswire
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
↗
February 13, 2025
Via
Benzinga
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
February 13, 2025
From
Merus N.V.
Via
GlobeNewswire
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
February 05, 2025
From
Merus N.V.
Via
GlobeNewswire
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
January 12, 2025
From
Merus N.V.
Via
GlobeNewswire
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
↗
January 10, 2025
Via
Benzinga
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
December 16, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
December 07, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Scores Its First FDA Approval For Lung Cancer Drug
↗
December 05, 2024
FDA approves Merus' Bizengri as the first treatment for advanced NRG1 fusion-positive cancers. U.S. peak sales are estimated at $16.5 million.
Via
Benzinga
Jim Cramer: This Health Care Stock Is 'Very, Very Speculative'
↗
December 05, 2024
Jim Cramer called Allison Transmission a "storied company... terrific. It does great."
Via
Benzinga
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
December 04, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline
↗
December 02, 2024
Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key focus for analysts.
Via
Benzinga
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
↗
December 02, 2024
Via
Benzinga
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
December 02, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
December 01, 2024
From
Merus N.V.
Via
GlobeNewswire
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
↗
November 21, 2024
Via
Benzinga
Merus to Present at Upcoming Investor Conferences
November 06, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Receives FDA extension of PDUFA for zenocutuzumab
November 05, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
October 31, 2024
From
Merus N.V.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
